REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

NCT05632809 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: NKTR-255
DRUG: Durvalumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]